Patents by Inventor Heather R. Sanders
Heather R. Sanders has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10093985Abstract: Described herein are methods, compositions and kits directed to the detection of gene dysregulations such as those arising from gene fusions and/or chromosomal abnormalities, e.g., translocations, insertions, inversions and deletions. Samples containing dysregulated gene(s) of interest may show independent expression patterns for the 5? and 3? regions of the gene. The methods, compositions and kits are useful for detecting mutations that cause the differential expression of a 5? portion of a target gene relative to the 3? region of the target gene.Type: GrantFiled: December 8, 2016Date of Patent: October 9, 2018Assignee: Quest Diagnostics Investments IncorporatedInventors: Heather R. Sanders, Maher Albitar, Aurelia Meloni-Ehrig
-
Patent number: 9963695Abstract: The invention provides methods for isolating RNA from whole urine and urine fractions for the diagnosis of prostate cancer and/or benign prostate hyperplasia. An exemplary method for diagnosing prostate cancer in an individual, said method comprises: (a) determining the amount of RNA encoding one or more diagnostic genes in the soluble urine fraction of a urine sample obtained from said individual; (b) comparing the amount of said RNA to a reference value for said one or more diagnostic genes, wherein said reference value is derived from the amount of RNA encoding said one or more diagnostic genes in one or more individuals that do not have prostate cancer; and (c) diagnosing said individual as having prostate cancer when the amount of said RNA is greater than said reference value.Type: GrantFiled: May 12, 2017Date of Patent: May 8, 2018Assignee: QUEST DIAGNOSTICS INVESTMENTS INCORPORATEDInventor: Heather R. Sanders
-
Patent number: 9957573Abstract: The present disclosure relates to methods for the diagnosis and evaluation of neoplastic disorders, particularly non-small cell lung cancer. Assays are described in which patient test samples are analyzed for the presence of one or more specific EML4-ALK fusion genes associated with neoplastic disorders.Type: GrantFiled: October 30, 2015Date of Patent: May 1, 2018Assignee: QUEST DIAGNOSTICS INVESTMENTS INCORPORATEDInventors: Heather R. Sanders, Maher Albitar, Aurelia Meloni-Ehrig
-
Publication number: 20180023145Abstract: Provided herein are methods and compositions for detection of a nucleic acid target in a sample. The methods and compositions use primer directed amplification in conjunction with nucleic acid fragmentation. The methods have high sensitivity even in the presence of a large amount of non-target nucleic acid. Also provided are oligonucleotides and kits useful in the method. Exemplary nucleic acid targets are those with mutant gene sequence such as mutant sequence of the EGFR, APC, TMPRSS2, ERG and ETV1 genes.Type: ApplicationFiled: September 22, 2017Publication date: January 25, 2018Applicant: Quest Diagnostics Investments IncorporatedInventors: Heather R. Sanders, Kevin Z. Qu, Charles M. Strom, Richard A. Bender
-
Publication number: 20170342402Abstract: The invention provides methods for isolating RNA from whole urine and urine fractions for the diagnosis of prostate cancer and/or benign prostate hyperplasia. An exemplary method for diagnosing prostate cancer in an individual, said method comprises: (a) determining the amount of RNA encoding one or more diagnostic genes in the soluble urine fraction of a urine sample obtained from said individual; (b) comparing the amount of said RNA to a reference value for said one or more diagnostic genes, wherein said reference value is derived from the amount of RNA encoding said one or more diagnostic genes in one or more individuals that do not have prostate cancer; and (c) diagnosing said individual as having prostate cancer when the amount of said RNA is greater than said reference value.Type: ApplicationFiled: May 12, 2017Publication date: November 30, 2017Applicant: Quest Diagnostics Investments IncorporatedInventor: Heather R. Sanders
-
Patent number: 9783854Abstract: Provided herein are methods and compositions for detection of a nucleic acid target in a sample. The methods and compositions use primer directed amplification in conjunction with nucleic acid fragmentation. The methods have high sensitivity even in the presence of a large amount of non-target nucleic acid. Also provided are oligonucleotides and kits useful in the method. Exemplary nucleic acid targets are those with mutant gene sequence such as mutant sequence of the EGFR, APC, TMPRSS2, ERG and ETV1 genes.Type: GrantFiled: April 6, 2015Date of Patent: October 10, 2017Assignee: Quest Diagnostics Investments IncorporatedInventors: Heather R. Sanders, Kevin Z. Qu, Charles M. Strom, Richard A. Bender
-
Publication number: 20170152572Abstract: Described herein are methods, compositions and kits directed to the detection of gene dysregulations such as those arising from gene fusions and/or chromosomal abnormalities, e.g., translocations, insertions, inversions and deletions. Samples containing dysregulated gene(s) of interest may show independent expression patterns for the 5? and 3? regions of the gene. The methods, compositions and kits are useful for detecting mutations that cause the differential expression of a 5? portion of a target gene relative to the 3? region of the target gene.Type: ApplicationFiled: December 8, 2016Publication date: June 1, 2017Applicant: Quest Diagnostics Investment IncorporatedInventors: Heather R. Sanders, Maher Albitar, Aurelia Meloni-Ehrig
-
Patent number: 9663781Abstract: The invention provides methods for isolating RNA from whole urine and urine fractions for the diagnosis of prostate cancer and/or benign prostate hyperplasia. An exemplary method for diagnosing prostate cancer in an individual, said method comprises: (a) determining the amount of RNA encoding one or more diagnostic genes in the soluble urine fraction of a urine sample obtained from said individual; (b) comparing the amount of said RNA to a reference value for said one or more diagnostic genes, wherein said reference value is derived from the amount of RNA encoding said one or more diagnostic genes in one or more individuals that do not have prostate cancer; and (c) diagnosing said individual as having prostate cancer when the amount of said RNA is greater than said reference value.Type: GrantFiled: December 29, 2011Date of Patent: May 30, 2017Assignee: QUEST DIAGNOSTICS INVESTMENTS INCORPORATEDInventor: Heather R. Sanders
-
Patent number: 9546404Abstract: Described herein are methods, compositions and kits directed to the detection of gene dysregulations such as those arising from gene fusions and/or chromosomal abnormalities, e.g., translocations, insertions, inversions and deletions. Samples containing dysregulated gene(s) of interest may show independent expression patterns for the 5? and 3? regions of the gene. The methods, compositions and kits are useful for detecting mutations that cause the differential expression of a 5? portion of a target gene relative to the 3? region of the target gene.Type: GrantFiled: April 29, 2015Date of Patent: January 17, 2017Assignee: QUEST DIAGNOSTICS INVESTMENTS INCORPORATEDInventors: Heather R. Sanders, Maher Albitar, Aurelia Meloni-Ehrig
-
Patent number: 9404159Abstract: Described herein are methods, compositions and kits directed to the detection the 5? portion of TMPRSS2 mRNA for the detection and diagnosis of prostate disease including prostate cancer and benign prostatic hyperplasia.Type: GrantFiled: September 9, 2013Date of Patent: August 2, 2016Assignee: QUEST DIAGNOSTICS INVESTEMENTS INCORPORATEDInventors: Heather R. Sanders, Maher Albitar
-
Publication number: 20160160289Abstract: The present disclosure relates to methods for the diagnosis and evaluation of neoplastic disorders, particularly non-small cell lung cancer. Assays are described in which patient test samples are analyzed for the presence of one or more specific EML4-ALK fusion genes associated with neoplastic disorders.Type: ApplicationFiled: October 30, 2015Publication date: June 9, 2016Applicant: Quest Diagnostics Investments IncorporatedInventors: Heather R. Sanders, Maher Albitar, Aurelia Meloni-Ehrig
-
Patent number: 9187788Abstract: Described herein are methods, compositions and kits directed to the detection of gene dysregulations such as those arising from gene fusions and/or chromosomal abnormalities, e.g., translocations, insertions, inversions and deletions. Samples containing dysregulated gene(s) of interest may show independent expression patterns for the 5? and 3? regions of the gene. The methods, compositions and kits are useful for detecting mutations that cause the differential expression of a 5? portion of a target gene relative to the 3? region of the target gene.Type: GrantFiled: August 7, 2014Date of Patent: November 17, 2015Assignee: QUEST DIAGNOSTICS INVESTMENTS INCORPORATEDInventors: Heather R. Sanders, Maher Albitar, Aurelia Meloni-Ehrig
-
Publication number: 20150315658Abstract: Described herein are methods, compositions and kits directed to the detection of gene dysregulations such as those arising from gene fusions and/or chromosomal abnormalities, e.g., translocations, insertions, inversions and deletions. Samples containing dysregulated gene(s) of interest may show independent expression patterns for the 5? and 3? regions of the gene. The methods, compositions and kits are useful for detecting mutations that cause the differential expression of a 5? portion of a target gene relative to the 3? region of the target gene.Type: ApplicationFiled: April 29, 2015Publication date: November 5, 2015Applicant: Quest Diagnostics Investments IncorporatedInventors: Heather R. Sanders, Maher Albitar, Aurelia Meloni-Ehrig
-
Patent number: 9175350Abstract: The present disclosure relates to methods for the diagnosis and evaluation of neoplastic disorders, particularly non-small cell lung cancer. Assays are described in which patient test samples are analyzed for the presence of one or more specific EML4-ALK fusion genes associated with neoplastic disorders.Type: GrantFiled: December 16, 2010Date of Patent: November 3, 2015Assignee: QUEST DIAGNOSTICS INVESTMENTS INCORPORATEDInventors: Heather R. Sanders, Aurelia Meloni-Ehrig
-
Publication number: 20150299811Abstract: Provided herein are methods and compositions for detection of a nucleic acid target in a sample. The methods and compositions use primer directed amplification in conjunction with nucleic acid fragmentation. The methods have high sensitivity even in the presence of a large amount of non-target nucleic acid. Also provided are oligonucleotides and kits useful in the method. Exemplary nucleic acid targets are those with mutant gene sequence such as mutant sequence of the EGFR, APC, TMPRSS2, ERG and ETV1 genes.Type: ApplicationFiled: April 6, 2015Publication date: October 22, 2015Applicant: Quest Diagnostics Investments IncorporatedInventors: Heather R. Sanders, Kevin Z. Qu, Charles M. Strom, Richard A. Bender
-
Patent number: 8999634Abstract: Provided herein are methods and compositions for detection of a nucleic acid target in a sample. The methods and compositions use primer directed amplification in conjunction with nucleic acid fragmentation. The methods have high sensitivity even in the presence of a large amount of non-target nucleic acid. Also provided are oligonucleotides and kits useful in the method. Exemplary nucleic acid targets are those with mutant gene sequence such as mutant sequence of the EGFR, APC, TMPRSS2, ERG and ETV1 genes.Type: GrantFiled: February 21, 2008Date of Patent: April 7, 2015Assignee: Quest Diagnostics Investments IncorporatedInventors: Heather R. Sanders, Kevin Z. Qu, Charles M. Strom, Richard A. Bender
-
Publication number: 20150038367Abstract: Described herein are methods, compositions and kits directed to the detection of gene dysregulations such as those arising from gene fusions and/or chromosomal abnormalities, e.g., translocations, insertions, inversions and deletions. Samples containing dysregulated gene(s) of interest may show independent expression patterns for the 5? and 3? regions of the gene. The methods, compositions and kits are useful for detecting mutations that cause the differential expression of a 5? portion of a target gene relative to the 3? region of the target gene.Type: ApplicationFiled: August 7, 2014Publication date: February 5, 2015Applicant: Quest Diagnostics Investments IncorporatedInventors: Heather R. Sanders, Maher Albitar, Aurelia Meloni-Ehrig
-
Patent number: 8815516Abstract: Described herein are methods, compositions and kits directed to the detection of gene dysregulations such as those arising from gene fusions and/or chromosomal abnormalities, e.g., translocations, insertions, inversions and deletions. Samples containing dysregulated gene(s) of interest may show independent expression patterns for the 5? and 3? regions of the gene. The methods, compositions and kits are useful for detecting mutations that cause the differential expression of a 5? portion of a target gene relative to the 3? region of the target gene.Type: GrantFiled: March 22, 2013Date of Patent: August 26, 2014Assignee: Quest Diagnostics Investments IncorporatedInventors: Heather R. Sanders, Maher Albitar, Aurelia Meloni-Ehrig
-
Publication number: 20140072972Abstract: Described herein are methods, compositions and kits directed to the detection the 5? portion of TMPRSS2 mRNA for the detection and diagnosis of prostate disease including prostate cancer and benign prostatic hyperplasia.Type: ApplicationFiled: September 9, 2013Publication date: March 13, 2014Applicant: Quest Diagnostics Investments IncorporatedInventors: Heather R. Sanders, Maher Albitar
-
Publication number: 20130344495Abstract: The invention provides methods for isolating RNA from whole urine and urine fractions for the diagnosis of prostate cancer and/or benign prostate hyperplasia. An exemplary method for diagnosing prostate cancer in an individual, said method comprises: (a) determining the amount of RNA encoding one or more diagnostic genes in the soluble urine fraction of a urine sample obtained from said individual; (b) comparing the amount of said RNA to a reference value for said one or more diagnostic genes, wherein said reference value is derived from the amount of RNA encoding said one or more diagnostic genes in one or more individuals that do not have prostate cancer; and (c) diagnosing said individual as having prostate cancer when the amount of said RNA is greater than said reference value.Type: ApplicationFiled: December 29, 2011Publication date: December 26, 2013Inventor: Heather R. Sanders